Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer
- PMID: 33657816
- DOI: 10.48095/ccko202126
Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer
Abstract
Ovarian cancer is one of the most common gynecologic cancers with the highest mortality rate over a long period. Genetic predisposition to ovarian cancer is unusually high. In the Czech Republic, causal mutation in any ovarian cancer predisposition gene is identified in approximately 30% of the ovarian cancer patients. Therefore, according to the current guidelines, all ovarian cancer patients should be provided with genetic testing. The BRCA1 and BRCA2 are the two major ovarian cancer predisposition genes. Nevertheless, mutations in other predisposition genes, including RAD51C and RAD51D, are associated with high ovarian cancer risk. Mutations in RAD51C and RAD51D are found in 1% of ovarian cancer patients in each respective gene. Currently, identification of germline mutation in RAD51C and RAD51D is primarily of preventive importance but it potentially could make a prognostic difference. The aim of this review is to summarize the recent RAD51C and RAD51D knowledge, including the biological function, cancer risks associated with germline mutations, and recommendations for mutation carriers.
Keywords: DNA repair; cancer genes; genetic testing; mutation; next gen sequencing; next generation sequencing; ovarian cancer; ovarian neoplasms.
Similar articles
-
Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.PLoS One. 2015 Jun 9;10(6):e0127711. doi: 10.1371/journal.pone.0127711. eCollection 2015. PLoS One. 2015. PMID: 26057125 Free PMC article.
-
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.J Clin Oncol. 2015 Sep 10;33(26):2901-7. doi: 10.1200/JCO.2015.61.2408. Epub 2015 Aug 10. J Clin Oncol. 2015. PMID: 26261251 Free PMC article.
-
BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.J Ovarian Res. 2020 May 2;13(1):50. doi: 10.1186/s13048-020-00654-3. J Ovarian Res. 2020. PMID: 32359370 Free PMC article.
-
A decade of RAD51C and RAD51D germline variants in cancer.Hum Mutat. 2022 Mar;43(3):285-298. doi: 10.1002/humu.24319. Epub 2021 Dec 30. Hum Mutat. 2022. PMID: 34923718 Review.
-
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6. Klin Onkol. 2019. PMID: 31409076 Review. English.
Cited by
-
The Curcumin Analog PAC Is a Potential Solution for the Treatment of Triple-Negative Breast Cancer by Modulating the Gene Expression of DNA Repair Pathways.Int J Mol Sci. 2023 Jun 2;24(11):9649. doi: 10.3390/ijms24119649. Int J Mol Sci. 2023. PMID: 37298600 Free PMC article.
-
Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.Mol Genet Genomic Med. 2023 Apr;11(4):e2125. doi: 10.1002/mgg3.2125. Epub 2022 Dec 19. Mol Genet Genomic Med. 2023. PMID: 36537080 Free PMC article.
-
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.Mol Cancer. 2024 Jan 9;23(1):9. doi: 10.1186/s12943-023-01925-5. Mol Cancer. 2024. PMID: 38195537 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous